BIOHEART-B (02185) announced its interim results for the six months ended June 30, 2025, reporting revenue of RMB 20.862 million. The company recorded a loss attributable to owners of the parent company of RMB 27.213 million, representing a year-on-year increase of 5.35%. Basic loss per share stood at RMB 0.11.

According to the announcement, the company's revenue for the six-month period ended June 30, 2025, was generated from the commercialization of RDN products. For the six months ended June 30, 2025, the company recognized revenue of RMB 20.9 million (compared to nil for the six months ended June 30, 2024), comprising RMB 20.5 million from product sales and RMB 0.4 million from partnerships.

The company's research and development expenses decreased, primarily attributed to a reduction of RMB 2.3 million in depreciation and amortization expenses, as the majority of machinery and equipment were utilized for production activities.